Pharmacological basics of f-current inhibition

HeartDrug

Volumn 5, Issue 1, 2005, Pages 14-20

  Mahlberg Gaudin, Florence H ^a   Bouly, Muriel ^a   Chezaubernard, Claire ^a   Lerebours, Guy ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

f current; Heart rate; Inhibition; Ischemia; Pacemaker current

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE; PROPRANOLOL; ZATEBRADINE;

AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; DIASTOLE; EXERCISE; HEART AUTOMATICITY; HEART BEAT; HEART CONDUCTION; HEART DEPOLARIZATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART OUTPUT; HEART PROTECTION; HEART RATE; HUMAN; ION CURRENT; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SINUS NODE; VASCULAR RESISTANCE;

EID: 13244263042     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083381     Document Type: Conference Paper

References (44)

1. Aronow WS, Ahn C, Mercando AD, Epstein S: Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996;78:1175-1176.
2. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA: Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 1987;113:1489-1494.
3. Kristal-Boneh E, Silber H, Harari G, Froom P: The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight-year follow-up of 3,527 male Israeli employees (the CORDIS Study). Eur Heart J 2000;21:116-124.
4. Mensink GB, Hoffmeister H: The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997;18:1404-1410.
5. Guth BD, Heusch G, Seitelberger R, Ross J Jr: Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 1987;60:738-746.
6. Singh BN: Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J 2003;5(suppl G):3-9.
7. Spahn DR, Frasco PE, White WD, Smith LR, Mac-Rae RL, Leone BJ: Is esmolol cardioprotective? Tolerance of pacing tachycardia, acute afterloading and hemodilution in dogs with coronary stenosis. J Am Coll Cardiol 1993;21:809-821.
8. DiFrancesco D: Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature 1986;324:470-473.
9. f) in sino-atrial node myocytes. Pflügers Arch 1994;427:64-70.
10. f in rabbit sinoatrial node cells by zatebradine (ULFS 49). On the mode of action of sinus node inhibitors. Circulation 1993;88(5 Pt 1):2389-2401.
11. f) in guinea-pig dissociated sinoatrial node cells. Br J Pharmacol 1993;110:343-349.
12. Shin KS, Rothberg BS, Yellen G: Blocker state dependence and trapping in hyperpolarizationactivated cation channels: Evidence for an intracellular activation gate. J Gen Physiol 2001;117:91-101.
13. Murphy JD, Pepine CJ: Sinus node inhibitors: Zatebradine and other agents; in Messerli FH (ed): Cardiovascular Drug Therapy. Philadelphia, Saunders, 1996, pp 1386-1394.
14. DiFrancesco D: The onset and autonomic regulation of cardiac pacemaker activity: Relevance of the f current. Cardiovasc Res 1995;29:449-456.
15. DiFrancesco D: Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol 1993;55:455-472.
16. Boyett MR, Honjo H, Kodama I: The sinoatrial node, a heterogeneous pacemaker structure. Cardiovasc Res 2000;47:658-687.
17. Robinson RB, DiFrancesco D: Sinoatrial node and impulse initiation; in Spooner PM, Rosen MR (eds): Foundations of Cardiac Arrhythmias: Basic Concepts and Clinical Approaches. New York, Dekker, 2001, pp 151-170.
18. 2+ channels in cardiac pacemaker activity. Proc Natl Acad Sci USA 2003;100:5543-5548.
19. f) plays an important role in regulating SA node pacemaker activity. Cardiovasc Res 1995;30:307-308.
20. Brown HF, DiFrancesco D, Noble SJ: How does adrenaline accelerate the heart? Nature 1979;280:235-236.
21. DiFrancesco D, Tortora P: Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 1991;351:145-147.
22. Biel M, Ludwig A, Zong X, Hofmann F: Hyperpolarization-activated cation channels: A multi-gene family. Rev Physiol Biochem Pharmacol 1999;136:165-181.
23. Kaupp UB, Seifert R: Molecular diversity of pacemaker ion channels. Annu Rev Physiol 2001;63:235-257.
24. Moosmang S, Stieber J, Zong X, Biel M, Hofmann F, Ludwig A: Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues. Eur J Biochem 2001;268:1646-1652.
25. Thollon C, Cambarrat C, Vian J, Prost J, Peglion J, Vilaine J: Electrophysiological effects of S16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: Comparison with UL-FS 49. Br J Pharmacol 1994;112:37-42.
26. Thollon C, Bidouard JP, Cambarrat C, Lesage L, Reure H, Delescluse I, Vian J, Peglion JL, Vilaine JP: Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S16257. Eur J Pharmacol 1997;339:43-51.
27. DiFrancesco D, Camm JA: Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: A new therapeutic perspective in cardiovascular disease. Drugs 2004;64:1757-1765.
28. Bois P, Bescond J, Renaudon B, Lenfant J: Mode of action of bradycardic agent, S16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118:1051-1057.
29. f channels by ivabradine. J Gen Physiol 2002;120:1-13.
30. Gardiner SM, Kemp PA, March JE, Bennett T: Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 1995;115:579-586.
31. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A: Coronary and haemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659-666.
32. Vilaine JP, Thollon C, Villeneuve N: Procoralan, a new selective I(f) current inhibitor. Eur Heart J 2003;5(suppl G):G26-G35.
33. Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF, Berdeaux A: Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 2002;282:H672-H679.
34. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, Berdeaux A: Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003;284:H676-H682.
35. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A: Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004;308:236-240.
36. Vilaine JP, Bidouard JP, Lesage L, Reure H, Peglion JL: Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003;42:688-696.
37. Monnet X, Ghaleh B, Colin P, De Curzon OP, Giudicelli JF, Berdeaux A: Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001;299:1133-1139.
38. Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A: Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J 2004;25:579-586.
39. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C: Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679.
40. Bortone AS, Hess OM, Gaglione A, Suter T, Nonogi H, Grimm J, Krayenbuehl HP: Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation 1990;81:1225-1235.
41. Young MA, Knight DR, Vatner SF: Autonomic control of large coronary arteries and resistance vessels. Prog Cardiovasc Dis 1987;30:211-234.
42. f inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-823.
43. f current inhibitor ivabradine versus atenolol in stable angina. A 4-month randomised, doubleblind, multicenter trial (abstract). Eur Heart J 2003;24(suppl):20.
44. Wijns W: Clinical evidence of myocardial stunning; in Heyndrickx GR, Vatner SF, Wijns W (eds): Stunning, Hibernation, and Preconditioning: Clinical Pathophysiology of Myocardial Ischaemia. Philadelphia, Lippincott-Raven, 1997, pp 253-272.